George Plitas, MD - Making the Most of the New Era of Immuno-Oncology in TNBC: Essential Guidance for Surgeons on How to Maximize the Potential of Immunotherapies and Combinations in Advanced and Early-Stage Breast Cancer - a podcast by PVI, PeerView Institute for Medical Education

Go online to PeerView.com/GKC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Immunotherapies are addressing a big unmet need in triple-negative breast cancer (TNBC) due to limited treatment options, the aggressive nature of the disease, and poor patient outcomes. This PeerView Live MasterClass and Practicum provides a comprehensive overview of the evolving role of immune checkpoint inhibitors in TNBC, specifically directed to surgeons. Experts explain the biologic rationale for the use of cancer immunotherapies in TNBC and explore the clinical evidence supporting their use in advanced/metastatic TNBC, as well as neoadjuvant/adjuvant settings of early-stage TNBC. Additionally, the faculty provides guidance on the practicalities of patient/tumor evaluation and candidate selection for immunotherapies, including their use in the context of other treatment modalities, and detection and management of immune-related adverse events. Strategies for effective collaboration and coordination of care among surgeons, oncologists, and other specialists in the era of immuno-oncology are also shared. Upon completion of this activity, participants should be better able to: Review the biologic rationale and rational strategies for harnessing the immune system in the treatment of triple-negative breast cancer (TNBC), including combinatorial or sequential approaches with immune checkpoint inhibitors and other effective therapies that may enhance immunogenicity and improve outcomes, Evaluate the efficacy, safety, biomarker, and other key data from clinical trials assessing immunotherapy and immune-based combinations or sequential strategies with other effective treatment modalities throughout the continuum of TNBC, including early-stage (neoadjuvant/adjuvant settings) and advanced/metastatic disease, Integrate immunotherapies into treatment plans for patients with TNBC based on the latest evidence, indications, recommendations, disease stage/treatment setting, patient and tumor characteristics, and other relevant factors in the context of effective multidisciplinary collaboration.

Further episodes of PeerView Immunology

Further podcasts by PVI, PeerView Institute for Medical Education

Website of PVI, PeerView Institute for Medical Education